Cartesian Therapeutics downgraded by Oppenheimer
$RNAC
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $42.00 | Buy | BTIG Research |
| 8/6/2024 | Buy | TD Cowen | |
| 7/2/2024 | Outperform → Perform | Oppenheimer | |
| 6/4/2024 | $50.00 | Outperform | Oppenheimer |
| 5/24/2024 | $40.00 | Buy | Mizuho |
| 4/23/2024 | $2.00 → $54.00 | Buy | H.C. Wainwright |
| 4/23/2024 | $39.00 | Outperform | Leerink Partners |
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)